Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?
Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?
复制标题
DOI：
10.1007/s12015-021-10231-w
复制
发表时间：
2022-01
影响因子：
4.8
通讯作者：
Di Bernardo G
中科院分区：
文献类型：
--
作者：
Galderisi U;Peluso G;Di Bernardo G
间充质基质细胞(MSCs)存在于多种组织的基质成分中，包括多能干细胞、祖细胞和分化细胞。骨髓间充质干细胞因其再生能力和损伤后促进组织动态平衡的能力而迅速引起临床领域的广泛关注。近年来，主要从骨髓、脂肪组织和脐带分离的间充质干细胞已被用于治疗各种疾病的数百项临床试验。然而，除了一些成功之外，基于MSC的疗法也经历了几次失败。使用MSCs的新试验数量呈指数级增长；尽管如此，只有有限数量的试验才能获得完整的结果。这种缺乏无助于防止可能无效和不必要的临床试验。不成功研究的结果可能有助于规划新的治疗方法以改善临床结果。为了支持对试验结果的批判性分析，我们回顾了过去六年发表的MSC临床试验的最新进展。在已发表的416项试验中，大多数评估了MSCs在治疗心血管疾病、GvHD以及脑和神经疾病方面的有效性，尽管一些试验寻求治疗免疫系统疾病和伤口并修复组织。我们还报告了一些非正统的临床试验，其中包括不寻常的研究。
Mesenchymal stromal cells (MSCs), present in the stromal component of several tissues, include multipotent stem cells, progenitors, and differentiated cells. MSCs have quickly attracted considerable attention in the clinical field for their regenerative properties and their ability to promote tissue homeostasis following injury. In recent years, MSCs mainly isolated from bone marrow, adipose tissue, and umbilical cord—have been utilized in hundreds of clinical trials for the treatment of various diseases. However, in addition to some successes, MSC-based therapies have experienced several failures. The number of new trials with MSCs is exponentially growing; still, complete results are only available for a limited number of trials. This dearth does not help prevent potentially inefficacious and unnecessary clinical trials. Results from unsuccessful studies may be useful in planning new therapeutic approaches to improve clinical outcomes. In order to bolster critical analysis of trial results, we reviewed the state of art of MSC clinical trials that have been published in the last six years. Most of the 416 published trials evaluated MSCs’ effectiveness in treating cardiovascular diseases, GvHD, and brain and neurological disorders, although some trials sought to treat immune system diseases and wounds and to restore tissue. We also report some unorthodox clinical trials that include unusual studies.
登录
查看更多内容
DOI：
10.1016/j.jaccao.2020.09.001
发表时间：
2020-11
期刊：
JACC. CardioOncology
影响因子：
--
作者：
Bolli R;Perin EC;Willerson JT;Yang PC;Traverse JH;Henry TD;Pepine CJ;Mitrani RD;Hare JM;Murphy MP;March KL;Ikram S;Lee DP;O'Brien C;Durand JB;Miller K;Lima JA;Ostovaneh MR;Ambale-Venkatesh B;Gee AP;Richman S;Taylor DA;Sayre SL;Bettencourt J;Vojvodic RW;Cohen ML;Simpson LM;Lai D;Aguilar D;Loghin C;Moyé L;Ebert RF;Davis BR;Simari RD;Cardiovascular Cell Therapy Research Network (CCTRN)
通讯作者：
Cardiovascular Cell Therapy Research Network (CCTRN)
影响因子：
3
作者：
Chen, Yi-Te;Wei, Jyh-Ding;Hung, Shih-Chieh
通讯作者：
Hung, Shih-Chieh
DOI：
10.1007/978-1-4939-3584-0_8
发表时间：
2016-01-01
期刊：
MESENCHYMAL STEM CELLS, 2 EDITION
影响因子：
--
作者：
Ciuffreda, Maria Chiara;Malpasso, Giuseppe;Gnecchi, Massimiliano
通讯作者：
Gnecchi, Massimiliano
影响因子：
4.8
作者：
Bolli, Roberto;Hare, Joshua M.;Simari, Robert D.
通讯作者：
Simari, Robert D.
影响因子：
4.5
作者：
Harris, Violaine K.;Vyshkina, Tamara;Sadiq, Saud A.
通讯作者：
Sadiq, Saud A.